A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients with Advanced or Metastatic Urothelial Carcinoma

NOT ENROLLING
Protocol # :
20-521
Conditions
Urothelial Carcinoma
Urothelial Carcinoma Bladder
Urothelial Carcinoma Ureter
Urothelial Carcinoma of the Renal Pelvis and Ureter
Urothelial Carcinoma Urethra
Phase
II
Disease Sites
Urinary Bladder
Principal Investigator
Wei, Xiao, Xiao
Site Research Nurses
Aspinwall, Sheridan
Engel, Lauren, E.
Lagerstedt, Elizabeth
Leisner, Claire
Mingrino, Sage
Pace, Amanda
Prisby, Judith
Salabao, Cristina
Theodore, Catherine
Walsh, Meghara

Trial Description

The study will evaluate the clinical activity of PD-(L)1 Checkpoint Inhibitor regimens in
combination with the investigational agent sitravatinib in patients with advanced or
metastatic urothelial carcinoma.

Eligibility Requirements

Inclusion Criteria:

- Diagnosis of urothelial carcinoma

- Adequate bone marrow and organ function

Exclusion Criteria:

- Uncontrolled tumor in the brain

- Unacceptable toxicity with prior checkpoint inhibitor

- Impaired heart function

20-521